Astragaloside-IV Alleviates High Glucose-induced Ferroptosis in Retinal Pigment Epithelial Cells by Disrupting the Expression of MiR-138-5p/Sirt1/Nrf2
Overview
Authors
Affiliations
Astragaloside-IV (AS-IV) (CHO) is a high-purity natural product extracted from , which has demonstrated biological activities. However, the effect of AS-IV on retinal pigment epithelial (RPE) cells in diabetic retinopathy (DR) remains unclear. In this study, high glucose (HG) was shown to promote ARPE-19 RPE cell death, increase the contents of reactive oxygen species (ROS) and oxidized glutathione (GSSG), and enhance lipid peroxidation density of mitochondrial membrane. In contrast, AS-IV decreased glutathione (GSH) content, mitochondria size and ridge. Addition of iron death inhibitor Ferrostatin-1 (Fer-1) to RPE cells decreased cell dead rate, thus indicating that HG-induced mitochondrial damage occurred due to ferroptosis. AS-IV alleviated HG-induced RPE cell damage. Furthermore, HG decreased levels of silent information regulator 1 (Sirt1) and nuclear factor (erythroid-derived 2)-like 2 (Nrf2) in the nucleus of RPE cells; AS-IV could alleviate these effects and increased expression of glutathione peroxidase 4 (GPX4), glutamate cysteine ligase (GCLM) and glutamate cysteine ligase catalytic subunit (GCLC), which are Nrf2 downstream genes. Mechanistically, AS-IV was shown to alleviate the effects of HG by increasing mir-138-5p expression in RPE cells and promoting expression of Sirt1 and Nrf2 in the nucleus. Transfection of mir-138-5p agonist inhibited the regulatory effects of AS-IV on Sirt1 and Nrf2, accompanied by decreased GPX4, GCLM and GCLC levels, and restoration of ferroptosis-related changes. Collectively, HG increased ferroptosis rate in RPE cells. In addition, AS-IV inhibited miR-138-5p expression, subsequently increasing Sirt1/Nrf2 activity and cellular antioxidant capacity to alleviate ferroptosis, resulting decreased cell death, which potentially inhibits the DR pathological process.
Yu H, Wang L, Yan X, Wu X, Wu J, Liu D Curr Med Sci. 2025; 45(1):93-103.
PMID: 40014196 PMC: 11906496. DOI: 10.1007/s11596-025-00011-9.
Ouyang F, Zheng M, Li J, Huang J, Ye J, Wang J Sci Rep. 2025; 15(1):2867.
PMID: 39843796 PMC: 11754889. DOI: 10.1038/s41598-025-86991-z.
Immune imbalance in Lupus Nephritis: The intersection of T-Cell and ferroptosis.
Fan Y, Ma K, Lin Y, Ren J, Peng H, Yuan L Front Immunol. 2024; 15:1520570.
PMID: 39726588 PMC: 11669548. DOI: 10.3389/fimmu.2024.1520570.
Methylglyoxal: A Key Factor for Diabetic Retinopathy and Its Effects on Retinal Damage.
Klochkov V, Chan C, Lin W Biomedicines. 2024; 12(11).
PMID: 39595078 PMC: 11592103. DOI: 10.3390/biomedicines12112512.
Epigenetics-targeted drugs: current paradigms and future challenges.
Dai W, Qiao X, Fang Y, Guo R, Bai P, Liu S Signal Transduct Target Ther. 2024; 9(1):332.
PMID: 39592582 PMC: 11627502. DOI: 10.1038/s41392-024-02039-0.